Assessment of Bioequivalence
Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.
- Solubility based on highest dose strength of an IR product
- Establishment of bioequivalence criteria
- Drugs possessing narrow therapeutic index
- Waivers of In Vivo Study Requirements
- Biopharmaceutics Classification System (BCS)
- Topical dosage forms
- Respiratory dosage forms
- Transdermal dosage forms
- Evaluation of highly variable drugs and drug product
Related Conference of Assessment of Bioequivalence
Assessment of Bioequivalence Conference Speakers
Recommended Sessions
- Bioequivalence Protocols: In vivo/ In vitro studies
- Contract Research Organization
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE studies of Biologics and Biosimilars
- Bioavailability
- Bioequivalence
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trails
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trails
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs
Related Journals
Are you interested in
- 3D Structure Determination - Structural Biology-2026 (France)
- Advanced Drug Delivery Systems for Metabolic Therapy - DRUG CHEMISTRY CONF 2026 (France)
- Advanced Techniques in Structural Biology - Structural Biology-2026 (France)
- AI & Computational Structural Biology - Structural Biology-2026 (France)
- Biochemistry and Biophysics - Structural Biology-2026 (France)
- Biomarker-Guided Drug Development - DRUG CHEMISTRY CONF 2026 (France)
- Chemical Biology Tools in Metabolic Research - DRUG CHEMISTRY CONF 2026 (France)
- Computational Approach in Structural Biology - Structural Biology-2026 (France)
- Computational Drug Design and Molecular Modeling - DRUG CHEMISTRY CONF 2026 (France)
- Drug Designing and Biomarkers - Structural Biology-2026 (France)
- Drug Resistance and Therapeutic Durability - DRUG CHEMISTRY CONF 2026 (France)
- Enzyme Modulation Approaches in Antidiabetic Drug Design - DRUG CHEMISTRY CONF 2026 (France)
- Epigenetic Regulation and Small-Molecule Therapeutics - DRUG CHEMISTRY CONF 2026 (France)
- Future Directions in Drug Chemistry for Diabetes Management - DRUG CHEMISTRY CONF 2026 (France)
- Hybrid Approaches for Structure Prediction - Structural Biology-2026 (France)
- Lipid Chemistry and Metabolic Regulation - DRUG CHEMISTRY CONF 2026 (France)
- Medicinal Chemistry Strategies for Metabolic Disorders - DRUG CHEMISTRY CONF 2026 (France)
- Membrane Proteins and Receptors - Structural Biology-2026 (France)
- Molecular Modelling and Dynamics - Structural Biology-2026 (France)
- Natural Product Chemistry in Diabetes Drug Discovery - DRUG CHEMISTRY CONF 2026 (France)
- Oxidative Stress Modulation through Drug Chemistry - DRUG CHEMISTRY CONF 2026 (France)
- Peptide and Protein-Based Drug Chemistry - DRUG CHEMISTRY CONF 2026 (France)
- Pharmacokinetics and Drug Metabolism Studies - DRUG CHEMISTRY CONF 2026 (France)
- Prodrug Design and Chemical Activation Strategies - DRUG CHEMISTRY CONF 2026 (France)
- Proteomics and Genomics - Structural Biology-2026 (France)
- Regulatory Chemistry and Drug Safety Assessment - DRUG CHEMISTRY CONF 2026 (France)
- Structural Bioinformatics and Computational Biology - Structural Biology-2026 (France)
- Structural Biology in Cancer Research - Structural Biology-2026 (France)
- Structural Virology - Structural Biology-2026 (France)
- Structural Virology and Infectious Diseases - Structural Biology-2026 (France)
- Structure-Based Drug Discovery - Structural Biology-2026 (France)
- Structure-Based Solutions to Global Health Challenges - Structural Biology-2026 (France)
- Structure-Function Relationships - Structural Biology-2026 (France)
- Structure–Activity Relationship Studies in Drug Chemistry - DRUG CHEMISTRY CONF 2026 (France)
- Synthetic Chemistry Innovations in Drug Development - DRUG CHEMISTRY CONF 2026 (France)
- Targeting Pancreatic Function through Drug Chemistry - DRUG CHEMISTRY CONF 2026 (France)
- The Structural Basis of Disease - Structural Biology-2026 (France)
- Translational Drug Chemistry from Bench to Clinic - DRUG CHEMISTRY CONF 2026 (France)
